论文部分内容阅读
目的探讨阿立哌唑治疗Tourette综合征(TS)的疗效和安全性。方法将82例TS患者按入组顺序分为研究组和对照组后分别予阿立哌唑(5～30mg/d)和氟哌啶醇(6～16mg/d)治疗8周。采用耶鲁抽动严重程度总体量表(YGTSS)、副反应量表(TESS)于治疗前、治疗第2、4、8周末对两组进行评估。结果研究组和治疗组在治疗第2、4、8周末两组YGTSS总分均较治疗前明显下降,差异均有统计学意义(t值为13.60～13.89和15.37～16.66,P均小于0.001)。两组间治疗前和治疗的第2、4、8周末YGTSS总分和减分率的差异均无统计学意义(总分差异主效应F=0.41,P=0.80;减分率差异主效应F=0.38,P=0.77),治疗的第2、4、8周末研究组TESS分低于对照组(秩和检验P均小于0.05)。结论阿立哌唑治疗TS的疗效与氟哌啶醇相当,且副作用较轻。
Objective To investigate the efficacy and safety of aripiprazole in the treatment of Tourette’s syndrome (TS). Methods Eighty-two patients with TS were divided into study group and control group according to the order of treatment group, and were treated with aripiprazole (5-30 mg / d) and haloperidol (6-16 mg / d) for 8 weeks respectively. Yale tic severity scale (YGTSS) and TESS were used to assess the two groups before treatment and at the end of the second, fourth and eighth week. Results The total score of YGTSS in study group and treatment group at the end of the 2nd, 4th, 8th week was significantly lower than that before treatment (t = 13.60 ~ 13.89 and 15.37 ~ 16.66, P <0.001) . There were no significant differences in YGTSS total scores and reduction rates between the two groups before treatment and the second, fourth and eighth weeks after treatment (F = 0.41, P = 0.80; Fractional rate difference main effect F = 0.38, P = 0.77). The TESS scores of the study group at the end of the 2nd, 4th, 8th week were lower than that of the control group (P <0.05). Conclusion The efficacy of aripiprazole in the treatment of TS is comparable to that of haloperidol and the side effects are mild.